Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer. - Wikidata - awgldk - TriplyDB

Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.

Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.

http://www.wikidata.org/entity/Q38090584

about

Standard chemotherapy with cetuximab for treatment of colorectal cancer KRAS mutation analysis by PCR: a comparison of two methods.Role of cetuximab in first-line treatment of metastatic colorectal cancer Impact of cetuximab in current treatment of metastatic colorectal cancer.Personalized treatment for patients with colorectal cancer: role of biomarkers.Variation in KRAS driver substitution distributions between tumor types is determined by both mutation and natural selection.The role of cell-free DNA in predicting colorectal cancer prognosis.Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab).On-treatment markers as predictors to guide anti-EGFR MoAb treatment in metastatic colorectal cancer: a systematic review with meta-analysis.Late, never or non-existent: the inaccessibility of preclinical evidence for new drugs Colorectal carcinomas, KRAS p.G13D mutant allele-specific imbalance, and anti-epidermal growth factor receptor therapy.

P2860

Q28088693-353A6F7A-A576-4C3F-8DDA-F3D9FDBF5A43 Q34876437-B8484986-E7A8-4163-AB06-3355527F09B5 Q37708010-9B0BB131-97B7-41B8-A94E-5E47073C4019 Q38183447-F522B3F5-ABC8-4CFA-B89B-4A87C6E9DA4E Q38390834-49FDFB4C-67C8-4812-8530-95BD177FE6E6 Q38594037-694CFC41-630C-41C6-BAC0-93BD6F02C194 Q38637642-84491380-7D3F-4E9F-9ECB-176EA8C05BF0 Q38906609-DCDD7B17-72F9-457C-870B-2DC873D5242C Q39017641-AA5F6E5B-40F2-405C-88F8-59D496929683 Q42038615-4763F52F-35A9-4B86-AA46-97FFD9D72B4D Q45242698-F1F0D4B1-7549-444F-B873-5BFC6EE33EED

P2860

Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.

http://www.wikidata.org/entity/Q38090584

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Controversies in antiepidermal ...... metastatic colorectal cancer.

@en

type

label

Controversies in antiepidermal ...... metastatic colorectal cancer.

@en

prefLabel

Controversies in antiepidermal ...... metastatic colorectal cancer.

@en

P1433

Q38090584-3BBB40D8-CE98-4FF7-A7A6-A30A766392ED

P1476

Q38090584-F36E9AD8-982E-4645-B4A2-486865074907

P2093

Q38090584-7062B14F-491B-4710-86BF-00A93D4275D6

Q38090584-9F1030C5-FC0F-4C0D-A8F9-96CEBB48F22A

Q38090584-B098B0CE-1BF2-4E68-B7B8-E959FFB2544C

Q38090584-CF56FF19-0D24-4764-9C77-7E24BE2EC197

P2860

Q38090584-072F6CA0-692E-4672-B064-29DA355F6F4D

Q38090584-1AA394FC-FB50-4985-A0CD-ACF171061E26

Q38090584-1E1D76FB-709C-4F4B-8CD5-3ECD1ADD27B8

Q38090584-24D44540-85A3-49F0-B405-23F3D3CFC8E3

Q38090584-2555083E-66BE-4B9D-B693-9318D37BC9CA

Q38090584-2AE77E63-9504-4A76-9C99-1315247EDC22

Q38090584-30FDC2E7-0BD7-417B-8B25-7AF809A7D04E

Q38090584-3AF4AF29-5435-43D1-9463-6DAFF5A7A26B

Q38090584-427F78D9-5D8F-4268-8299-FF4BDA9927C1

Q38090584-48FF3B2D-AB29-4376-BB20-183D2CBA41D4

P304

Q38090584-BA6EF327-8E02-457A-9E1D-5B99D4798A9F

P31

Q38090584-12E10829-D72C-451C-83F1-DD01EDDE4713

P356

Q38090584-7DD2ED44-A01E-42AD-8AF5-EE3934BFC6AA

P407

Q38090584-E7F6B4A5-8E02-4041-9B5A-008D3AE0ED9E

P433

Q38090584-68536173-FDB9-4DEF-87E8-5C5D0FA1A825

P478

Q38090584-FD180623-44D2-48A7-9B54-AA1D663DD54F

P577

Q38090584-AF02A384-2107-40F0-9729-FF10136F8BDD

P698

Q38090584-95DDCB39-7FD1-48A7-A4E6-727C279384BE

P921

Q38090584-60DD3066-51D8-4089-B8FF-340183ED4CAA

P356

P1433

P1476

Controversies in antiepidermal ...... metastatic colorectal cancer.

@en

P2093

Janghee Woo

http://www.w3.org/2001/XMLSchema#string

John C Leighton

http://www.w3.org/2001/XMLSchema#string

Neil Palmisiano

http://www.w3.org/2001/XMLSchema#string

William Tester

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Cetuximab for the treatment of colorectal cancer.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer

Circulating mutant DNA to assess tumor dynamics

P304

1941-1950

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.27994

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23504768

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer